Moderna, Inc.(MRNA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,768 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MRNA Stock Analysis & AI Quality Score
Data updated 2026-09-12AI stock analysis and institutional research for Moderna, Inc. (MRNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRNA at 21.2/100 on a 32-signal composite quality model, placing it at rank #2,768 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (6.4) and balance sheet strength (8.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Moderna, Inc. reports quarterly revenue of $145.0M, net income of $-782.0M, free cash flow of $-563.0M. Top institutional holders of MRNA by reported 13-F value include FMR, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MRNA trades on the Nasdaq exchange and files with the SEC under CIK 1682852. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Moderna, Inc. directly from SEC EDGAR. Moderna, Inc.'s 13F Pro composite quality score has ranged between 13 and 91 since 2021, currently 21.2 — a declining long-term trajectory across 69 quarterly and live scoring snapshots.
Revenue
Q2 2026
$145.0M
Net Income
Q2 2026
$-782.0M
Free Cash Flow
Q2 2026
$-563.0M
ROIC
Q2 2026
-44.3%
D/E Ratio
Q2 2026
0.09
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-39.9% YoYNet Income
+20.8% YoYOperating Income
+22.1% YoYEPS (Diluted)
+21.8% YoYTotal Assets
-12.8% YoYTotal Debt
Op. Cash Flow
+37.6% YoYFree Cash Flow
+49.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.94B -39.9% | $3.24B -52.7% | $6.85B -64.4% | $19.26B +4.3% | $18.47B +2200.2% | $803.0M |
| Net Income | $-2.82B +20.8% | $-3.56B +24.5% | $-4.71B -156.4% | $8.36B -31.5% | $12.20B +1733.5% | $-747.0M |
| Operating Income | $-3.07B +22.1% | $-3.94B +6.9% | $-4.24B -145.0% | $9.42B -29.2% | $13.30B +1842.6% | $-763.0M |
| EPS (Diluted) | $-7.26 +21.8% | $-9.28 +24.7% | $-12.33 -161.3% | $20.12 -28.9% | $28.29 +1543.4% | $-1.96 |
| Total Assets | $12.34B -12.8% | $14.14B -23.2% | $18.43B -28.7% | $25.86B +4.8% | $24.67B +236.2% | $7.34B |
| Total Debt | $590.0M | $0.00 | — | — | — | — |
| Operating Cash Flow | $-1.87B +37.6% | $-3.00B +3.7% | $-3.12B -162.6% | $4.98B -63.4% | $13.62B +571.9% | $2.03B |
| Free Cash Flow | $-2.06B +49.1% | $-4.05B -6.0% | $-3.83B -183.5% | $4.58B -65.6% | $13.34B +580.8% | $1.96B |
Get alerted when MRNA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Moderna, Inc. including:
Top Institutional Holders of MRNA
FMR LLC
$3.6B51,859,891 shBlackRock, Inc.
$2.1B30,599,409 shVANGUARD CAPITAL MANAGEMENT LLC
$1.6B23,208,792 shCapital World Investors
$1.6B22,276,996 shBAILLIE GIFFORD & CO
$1.3B18,206,778 shSTATE STREET CORP
$1.1B15,726,193 shVANGUARD PORTFOLIO MANAGEMENT LLC
$1.1B15,581,313 shGEODE CAPITAL MANAGEMENT, LLC
$678.8M9,710,335 shMORGAN STANLEY
$668.0M9,538,094 shTheleme Partners LLP
$564.3M8,057,571 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $3.6B | 51,859,891 |
| BlackRock, Inc. | $2.1B | 30,599,409 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.6B | 23,208,792 |
| Capital World Investors | $1.6B | 22,276,996 |
| BAILLIE GIFFORD & CO | $1.3B | 18,206,778 |
| STATE STREET CORP | $1.1B | 15,726,193 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.1B | 15,581,313 |
| GEODE CAPITAL MANAGEMENT, LLC | $678.8M | 9,710,335 |
| MORGAN STANLEY | $668.0M | 9,538,094 |
| Theleme Partners LLP | $564.3M | 8,057,571 |
Companies Similar to MRNA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CRISPR Therapeutics AG
IONIS PHARMACEUTICALS INC
Viatris Inc
Sarepta Therapeutics, Inc.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOVAVAX INC
Tilray Brands, Inc.
Teladoc Health, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MRNA on your watchlist
Track score changes the day Moderna, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MRNA a good stock to buy?
13F Pro's AI-powered analysis of Moderna, Inc. (MRNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MRNA are available on the MRNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MRNA is classified as a large company.
Which hedge funds own MRNA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MRNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Moderna, Inc.'s investment landscape.